TECENTRIQ HYQEVO
Live / Applied — Fifth extension granted (statement of use) (as of 21 Jan 2026)
What this means for you
Not registered yet, but its 30 Mar 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97338551
- Mark type
- Stylized text
- Filed
- 30 Mar 2022
- Published for opposition
- 30 May 2023
- Attorney of record
- Jelena Libby
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, applied subcutaneously and containing atezolizumab, for the treatment of oncological disorders and diseases
Owner
- Genentech, Inc., South San Francisco, CA, US
- Genentech, Inc., South San Francisco, CA, US
Prosecution history
- 21 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 21 Jan 2026 — SOU EXTENSION 5 GRANTED
- 20 Jan 2026 — SOU EXTENSION 5 FILED
- 20 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 16 Dec 2025 — ITU LETTER MAILED, NO RESPONSE REQUIRED
- 16 Dec 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 22 Jul 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 21 Jul 2025 — SOU TEAS EXTENSION RECEIVED
- 21 Jul 2025 — SOU EXTENSION 4 GRANTED
- 21 Jul 2025 — SOU EXTENSION 4 FILED
- 21 Jul 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 22 Jan 2025 — SOU EXTENSION 3 GRANTED
- 22 Jan 2025 — SOU EXTENSION 3 FILED
- 22 Jan 2025 — SOU TEAS EXTENSION RECEIVED